NeuroOne Medical Technologies Corporation set April 3, 2026 as the date for its 2026 annual meeting of stockholders. The company will provide the exact time, location, and voting items in a future proxy statement.
Because this date is more than 30 days later than the prior year’s meeting anniversary, stockholder proposals seeking inclusion in the 2026 proxy materials under Rule 14a-8 must be received at the company’s principal executive offices by March 4, 2026.
NEUROONE MEDICAL TECHNOLOGIES Corp Chief Technology Officer Steve Mertens reported a Form 4 transaction involving company common stock. On this date, 7,376 shares were disposed of at a price of $0.68 per share as a tax-withholding disposition rather than an open-market sale. Following this transaction, Mertens directly owned 153,047 shares of NEUROONE MEDICAL TECHNOLOGIES Corp common stock.
NeuroOne Medical Technologies Corp officer Mark Christianson reported a tax-related share disposition. On February 18, 2026, he disposed of 1,812 shares of common stock at $0.68 per share to cover tax withholding. Following this transaction, he directly owns 228,920 common shares of the company.
NEUROONE MEDICAL TECHNOLOGIES Corp CEO and President David A. Rosa reported a Form 4 transaction involving company common stock. On February 18, 2026, he disposed of 71,325 shares at $0.68 per share in a tax-withholding disposition related to equity compensation, not an open-market sale. After this transaction, he directly owned 1,082,590 common shares.
NeuroOne Medical Technologies Corporation reported fiscal first-quarter 2026 results and raised its outlook for the full year. For the quarter ended December 31, 2025, product revenue was $2.9 million, slightly below $3.3 million a year earlier due to a large initial stocking order in the prior-year period, but up 5.5% from $2.7 million in the previous quarter. Product gross profit was $1.6 million, or 54.2% of revenue.
The company reported a net loss of $1.4 million, or $0.03 per share, compared with net income of $1.8 million, or $0.06 per share, a year ago, when results included $3.0 million of one-time license revenue. As of December 31, 2025, NeuroOne held $3.6 million in cash and cash equivalents, $6.8 million of working capital, and no debt, and believes it is funded through fiscal 2026. Management now expects fiscal 2026 product revenue of at least $10.5 million, at least 17% higher than fiscal 2025.
NeuroOne Medical Technologies reported a net loss of $1.4 million for the quarter ended December 31, 2025, after earning $1.8 million in the prior-year period, mainly because last year included $3.0 million of one-time license revenue from its Zimmer agreement. Product revenue from its cleared neuromodulation devices was $2.9 million, down modestly from $3.3 million, and product gross margin slipped to 54.2% from 58.9% due to pricing mix and higher costs.
Cash and cash equivalents were $3.6 million at December 31, 2025, versus $6.6 million at September 30, 2025, as operating activities used $3.1 million of cash in the quarter. Management believes existing cash, expected Zimmer-related product revenues and planned expense reductions can fund operations through September 2026, but still states that substantial doubt exists about the company’s ability to continue as a going concern. NeuroOne remains highly dependent on a single major customer for product revenue and on third-party manufacturers, and it has received a Nasdaq notice for not meeting the minimum bid price requirement, with an extension to regain compliance by May 4, 2026.
NeuroOne Medical Technologies Corporation filed an Amendment No. 1 to its annual report to add the Part III sections that would normally come from its proxy, covering board structure, executive pay, ownership and auditor information.
The filing describes a three-class board led by non-executive chairman Paul Buckman, with separate audit, compensation, and nominating and corporate governance committees, all composed of Nasdaq-independent directors other than the CEO. It details 2025 compensation for CEO David Rosa (total $1,154,436), COO Christopher Volker and CFO Ronald McClurg, including base salaries, cash bonuses paid at 94% of target and significant stock option grants.
The amendment also discloses non-employee director retainers (generally $50,000, with $100,000 for the chair) plus equity awards, shows that Merchant Adventure Fund, L.P. beneficially owns 8.3% of common stock, and that all directors and officers as a group hold 11.8%. It notes related-party participation in a 2024 private placement and a 2025 public offering, and lists 2025 audit fees to Baker Tilly US, LLP of $407,111.
NeuroOne Medical Technologies Corporation filed a current report stating that on December 17, 2025 it issued a press release announcing its financial results for the fiscal quarter and year ended September 30, 2025.
The press release is furnished as Exhibit 99.1 and, along with Item 2.02, is treated as furnished rather than filed under the Exchange Act, which affects how it is incorporated into other Securities Act and Exchange Act filings. The company’s common stock trades on the Nasdaq Stock Market under the symbol NMTC.
NeuroOne Medical Technologies Corporation reports its annual update as a neurotechnology company developing thin-film electrodes for brain disorders, chronic pain and drug delivery. It now has four FDA 510(k)-cleared products: Evo cortical and sEEG diagnostic electrodes, the OneRF brain ablation system and the OneRF TN ablation system, with global brain distribution rights for brain applications licensed exclusively to Zimmer. Pipeline programs target spinal cord stimulation, basivertebral nerve ablation and agent-delivering neural electrodes.
The company relies on long-term licenses from WARF and Mayo and an amended Zimmer agreement that added OneRF distribution for a $3 million upfront payment plus potential sales milestones. An April 2025 equity offering of 18.4 million shares at $0.50 generated approximately $8.2 million of net proceeds, yet cash and cash equivalents were about $6.6 million as of September 30, 2025 against an accumulated deficit of $78.6 million. Auditors and management highlight substantial doubt about its ability to continue as a going concern, and Nasdaq has granted only a limited extension to regain the $1.00 minimum bid price.
NeuroOne Medical Technologies (NMTC) received a Nasdaq extension to regain compliance with the Nasdaq Capital Market’s Minimum Bid Price Requirement of $1.00 per share. Nasdaq granted a 180-day extension through May 4, 2026.
The extension has no immediate effect on the company’s listing; NMTC’s common stock remains fully listed on the Nasdaq Capital Market. The company previously had until November 3, 2025 to cure the deficiency and has not yet regained compliance.
NeuroOne plans to continue monitoring the closing bid price and to seek compliance within the extension period. If compliance is not regained by the new deadline, Nasdaq may notify the company that its common stock is subject to delisting, and the company would have the right to appeal to a Nasdaq Hearing Panel.